All companies › TARS

TARS · Tarsus Pharmaceuticals, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells13
Research cases0
Last filing2026-09-15

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-01 — Lin Elizabeth Yeu · sold 4,601 @ $73.86 2026-09-02 — Azamian Bobak R. · sold 10,000 @ $80.06 2026-09-02 — Lin Elizabeth Yeu · sold 1,590 @ $80.00 2026-09-02 — Lin Elizabeth Yeu · sold 5,387 @ $80.00 2026-09-04 — Neervannan Seshadri · sold 4,564 @ $85.00 2026-09-04 — Azamian Bobak R. · sold 2,900 @ $91.27 2026-09-04 — Azamian Bobak R. · sold 7,100 @ $90.27 2026-09-04 — Lin Elizabeth Yeu · sold 1,590 @ $90.00 2026-09-04 — Lin Elizabeth Yeu · sold 5,386 @ $90.00 2026-09-04 — Lin Elizabeth Yeu · sold 5,387 @ $85.00 2026-09-15 — LINK WILLIAM J PHD · sold 11,675 @ $78.33 2026-09-15 — LINK WILLIAM J PHD · sold 66 @ $80.01 2026-09-15 — LINK WILLIAM J PHD · sold 759 @ $79.00
2026-09-012026-09-15

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Lin Elizabeth Yeu Chief Medical Officer
Azamian Bobak R. President/CEO and Board Chair, Director
LINK WILLIAM J PHD Director
Neervannan Seshadri Chief Operating Officer
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $TARS is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-15', 'insider_name': 'LINK WILLIAM J PHD', 'insider_title': 'Director', 'transaction_type': 'Open-market sell', 'shares': 11675.0, 'price': 78.33, 'value': 914502.75, 'is_buy': False}, {'transaction_date': '2026-09-15', 'insider_name': 'LINK WILLIAM J PHD', 'insider_title': 'Director', 'transaction_type': 'Open-market sell', 'shares': 66.0, 'price': 80.01, 'value': 5280.66, 'is_buy': False}, {'transaction_date': '2026-09-15', 'insider_name': 'LINK WILLIAM J PHD', 'insider_title': 'Director', 'transaction_type': 'Open-market sell', 'shares': 759.0, 'price': 79.0, 'value': 59961.0, 'is_buy': False}, {'transaction_date': '2026-09-04', 'insider_name': 'Neervannan Seshadri', 'insider_title': 'Chief Operating Officer', 'transaction_type': 'Open-market sell', 'shares': 4564.0, 'price': 85.0, 'value': 387940.0, 'is_buy': False}, {'transaction_date': '2026-09-04', 'insider_name': 'Azamian Bobak R.', 'insider_title': 'President/CEO and Board Chair, Director', 'transaction_type': 'Open-market sell', 'shares': 2900.0, 'price': 91.27, 'value': 264683.0, 'is_buy': False}, {'transaction_date': '2026-09-04', 'insider_name': 'Azamian Bobak R.', 'insider_title': 'President/CEO and Board Chair, Director', 'transaction_type': 'Open-market sell', 'shares': 7100.0, 'price': 90.27, 'value': 640917.0, 'is_buy': False}, {'transaction_date': '2026-09-04', 'insider_name': 'Lin Elizabeth Yeu', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 1590.0, 'price': 90.0, 'value': 143100.0, 'is_buy': False}, {'transaction_date': '2026-09-04', 'insider_name': 'Lin Elizabeth Yeu', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 5386.0, 'price': 90.0, 'value': 484740.0, 'is_buy': False}, {'transaction_date': '2026-09-04', 'insider_name': 'Lin Elizabeth Yeu', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 5387.0, 'price': 85.0, 'value': 457895.0, 'is_buy': False}, {'transaction_date': '2026-09-02', 'insider_name': 'Azamian Bobak R.', 'insider_title': 'President/CEO and Board Chair, Director', 'transaction_type': 'Open-market sell', 'shares': 10000.0, 'price': 80.06, 'value': 800600.0, 'is_buy': False}, {'transaction_date': '2026-09-02', 'insider_name': 'Lin Elizabeth Yeu', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 1590.0, 'price': 80.0, 'value': 127200.0, 'is_buy': False}, {'transaction_date': '2026-09-02', 'insider_name': 'Lin Elizabeth Yeu', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 5387.0, 'price': 80.0, 'value': 430960.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Lin Elizabeth Yeu', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 4601.0, 'price': 73.86, 'value': 339829.86, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for TARS today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.